US09058V1035 - Common Stock - After market: 10.74 +0.16 (+1.51%)
NASDAQ:BCRX (1/27/2023, 7:00:00 PM)-0.2 (-1.86%)
|GICS Sector||Health Care|
|Earnings (Last)||11-01 2022-11-01/bmo||Earnings (Next)||02-21 2023-02-21|
|Ins Owners||1.42%||Inst Owners||79.54%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703
CEO: Jon P. Stonehouse
RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first...
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...
BioCryst Pharmaceuticals (BCRX) fell ~12% on Monday after announcing lower-than-expected sales for the company's hereditary angioedema therapy Orladeyo. Read the full story here.
—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in...
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH...
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.